CasInvent Pharma Receives Top Honor at Transfera Technology Days 2024

We are proud to announce that CasInvent Pharma has been awarded first place at the prestigious Transfera Technology Days 2024 for our project, "Highly Potent and Selective CK1 Kinase Inhibitors for the Treatment of Resistant Tumors." Out of 23 competing projects, this recognition highlights the strength of our research and its potential to make a significant impact.

Held on December 2, 2024, in Prague, Transfera Technology Days serves as an important platform that connects Czech science with business. The annual event assesses the commercial potential of scientific projects from Czech universities and research organizations, fostering opportunities for collaboration and engagement with investors.

Our project focuses on developing highly potent and selective inhibitors targeting CK1 kinases, offering a promising approach to treating resistant tumors. This honor reflects our commitment to advancing oncology research and finding innovative solutions to meet challenging medical needs.

We sincerely thank the organizers of Transfera Technology Days for creating an environment that celebrates scientific innovation and fosters valuable partnerships. This recognition motivates us to continue translating scientific breakthroughs into real-world applications that can benefit patients.

CasInvent Pharma remains dedicated to upholding the highest standards in research, strengthening the connection between academic discovery and industrial application. Together, we are determined to make a meaningful difference in the fight against cancer.